CD36 and breast cancer: Using breast cancer models of aromatase inhibitor resistance, Bacci et al. showed that nuclear factor kappa B (NF-κB) activation induced aberrant lipid metabolism characterized by increased intracellular lipid deposition, which was maintained by either novo FA synthesis or CD36-mediated VLCFA/BCFA uptake[31].